Featured Study Opportunities
The Crohn's & Colitis Foundation utilizes Featured Study Opportunities to collaborate with academic and industry researchers to help enroll patients with Crohn’s disease and ulcerative colitis into clinical studies. The list below highlights our partners' current research studies. Please note that these partners have paid to have their trials posted below. Some partners' studies listed may be recipients of partial or full funding from the Crohn's & Colitis Foundation. This support does not imply recommendation or favor of the Foundation, as the Crohn's & Colitis Foundation does not endorse any particular study.
For a comprehensive listing of all research studies currently recruiting, please click here.
(For e.g NY instead of New York)
Current Results: 95 entries
To evaluate whether an investigational treatment called EXE-346, a probiotic biologic drug, may help reduce bowel movement frequency in patients with an ileal pouch-anal anastomosis (IPAA or “j-pouch”).
The study aims to evaluate if the Investigational study drug (given as pills) can improve signs and symptoms of moderate to severe Crohn’s disease (CD), as well as to see if it has any side effects.
To evaluate two different drugs that block IL-23 pathway in the immune system are safe and effective to treat moderate to severe pediatric Crohn’s disease. These two drugs will not be compared against each other.
This platform study will evaluate the efficacy and safety of investigational treatments, including 3 investigational monotherapies and 3 combinations, for adults with moderately to severely active UC.
The purpose of this study is to evaluate the efficacy and safety of investigational product MORF-057 in participants with moderately to severely active Crohn's disease (CD).
The main purpose of the study is to evaluate the effectiveness and safety of the study drug LY4268989 when given with mirikizumab compared to mirikizumab alone in adult participants with moderately to severely active ulcerative colitis (UC).
This study is being done to test the effectiveness and safety of an investigational medication called SAR442970 compared to placebo in participants with moderate to severe ulcerative colitis (UC) who either have not responded to prior treatment or were unable to tolerate prior treatments.
The purpose of the CHROMA-CD study is to find out if SAR442970 is safe and effective in improving the symptoms of CD.
The primary objective of the registry is to estimate the prevalence of major congenital malformations among pregnant individuals with IBD who are exposed to an IBD pharmacotherapy during pregnancy.
The primary objective of this research is to evaluate specific and non-specific effects of hypnotherapy.
The secondary objective is to evaluate the efficacy of group-format gut-directed hypnotherapy delivered via telehealth for managing gastrointestinal health.
The Featured Study Opportunities page is made possible in part by:
